Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais

Jeremie Calais discusses his PCF funded research on 177 Lu-PSMA-617 with respect to resistance patterns that develop to treatment along with primary resistance.  Drs. Calais and Ryan discuss patient and tumor characteristics for both those demonstrating effectiveness to therapy and those that develop resistance or have primary resistance.

Biographies:


Jeremie Calais, MD, MSc Assistant Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology UCLA Nuclear Medicine Department Los Angeles, CA

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology and Transplantation.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe